Treatment of Hypoxia in Pulmonary Embolism

Initial Management of Hypoxemia

The European Society of Cardiology recommends administration of supplemental oxygen in all patients with pulmonary embolism and SaO2 <90%, with escalation of oxygen delivery methods as needed 1
For patients not responding to conventional oxygen supplementation, consider high-flow oxygen via nasal cannula as the next step in oxygen delivery, and non-invasive ventilation if high-flow oxygen is insufficient 1
Invasive mechanical ventilation should be reserved for cases of extreme instability, as positive pressure ventilation may worsen right ventricular failure 1

If non-invasive methods fail and intubation becomes necessary, use tidal volumes of approximately 6 mL/kg lean body weight, keep end-inspiratory plateau pressure <30 cm H2O, and apply positive end-expiratory pressure cautiously 1
Avoid anesthetic drugs that cause hypotension during intubation 1

Risk stratification should guide treatment approach, determining if the patient is high-risk, intermediate-risk, or low-risk, according to the European Heart Journal 2
For patients with hypotension and pulmonary embolism, vasopressive drugs are recommended, and dobutamine and/or norepinephrine should be considered, particularly those with hemodynamic compromise 3, 4
Aggressive fluid challenge is not recommended as it may worsen right ventricular failure 3

Anticoagulation should be initiated or continued without delay, as recommended by the European Heart Journal 2
For patients showing hemodynamic deterioration despite anticoagulation, rescue thrombolytic therapy is recommended, and surgical embolectomy or catheter-directed treatment should be considered if thrombolysis is contraindicated or fails 4

Delaying escalation of oxygen therapy when conventional supplementation is insufficient, as cautioned by the European Heart Journal 1
Overlooking right-to-left shunting through a patent foramen ovale as a cause of refractory hypoxemia, as noted in the European Heart Journal 1
Using aggressive fluid challenges in pulmonary embolism patients with right ventricular dysfunction, which can worsen hemodynamics, as warned by the European Heart Journal 3
Failing to consider rescue thrombolysis in patients with worsening hypoxemia and hemodynamic deterioration despite anticoagulation, as recommended by the European Heart Journal 4

The European Society of Cardiology recommends immediate systemic thrombolysis with tissue plasminogen activator (alteplase) infusion for patients with high-risk pulmonary embolism and hemodynamic instability 5, 6
High-risk pulmonary embolism is characterized by hemodynamic instability, including hypotension, tachycardia, and right ventricular dysfunction, as confirmed by CT scans and clinical presentation 5, 6
The presence of large bilateral pulmonary emboli on imaging and deteriorating hemodynamics despite vasopressor support are indications for thrombolytic therapy 5, 6

Systemic thrombolytic therapy is a Class I recommendation for patients with high-risk pulmonary embolism presenting with hemodynamic instability, according to the European Society of Cardiology guidelines 5, 6
The 2019 ESC guidelines upgraded rescue thrombolytic therapy from Class IIa to Class I for patients who deteriorate hemodynamically 6
Alteplase 50 mg IV bolus should be administered immediately in deteriorating patients, followed by unfractionated heparin after 3 hours, preferably weight-adjusted 7

Anticoagulation alone is insufficient for hemodynamically unstable patients, and rescue thrombolytic therapy is required 5, 6
Delaying thrombolysis while attempting other interventions in hemodynamically unstable pulmonary embolism is associated with increased mortality 5, 6
Failing to recognize hemodynamic deterioration as an indication for escalation from anticoagulation alone to reperfusion therapy can lead to poor outcomes 5, 6

Surgical embolectomy is recommended as an alternative or rescue option for high-risk pulmonary embolism when thrombolysis is contraindicated or has failed 5, 6
IVC filters are not routinely recommended in pulmonary embolism management and should only be considered when anticoagulation is absolutely contraindicated or in recurrent pulmonary embolism despite adequate anticoagulation 5